South Korea MFDS and EBC-46: Health Functional Food Framework for Botanical Supplements

South Korea's Ministry of Food and Drug Safety (MFDS, formerly KFDA) sits within a tightly defined regulatory architecture for botanical products that diverges meaningfully from US dietary supplement law. For brands selling EBC-46 supplements internationally, understanding how Korea's Health Functional Food (HFF) framework handles novel botanicals is useful context — both for what it permits and for what it requires manufacturers to disclose. This article summarises how blushwood berry extract supplements would be classified under Korean rules and what evidence regulators typically expect.

How Korea categorises supplements

Under the Health Functional Food Act, MFDS recognises two main categories: Notified HFF, which uses ingredients on a pre-approved list with established uses; and Individually Recognised HFF, which requires the manufacturer to submit safety and functionality dossiers for compounds not yet on the notified list. Blushwood berry extract is not on the notified list, so any Korean-market product would fall under the Individually Recognised pathway — a route that requires more substantial documentation than the US DSHEA framework.

Documentation expectations under MFDS

MFDS guidance for Individually Recognised HFFs typically expects four evidence categories: standardisation of the active ingredient, safety data (acute, sub-chronic, and where appropriate genotoxicity), human study data supporting any functional claim, and full manufacturing controls. Importantly, MFDS distinguishes between food-grade quality controls and therapeutic claims — products that meet HFF standards can describe a "function" but cannot claim to treat or prevent disease. This is structurally similar to the FDA's structure/function claim framework, although Korean enforcement is generally stricter on label wording.

Where blushwood berry extract sits today

No Korean manufacturer has, to public knowledge, filed an Individually Recognised HFF application for blushwood berry extract. This is consistent with the wider regulatory landscape: tigilanol tiglate as a pharmaceutical agent has only progressed through veterinary approval (Stelfonta) and early-stage human trials, while consumer-grade blushwood berry supplements are sold under the US DSHEA framework with no equivalent evidence package required for Korean entry. Korean consumers wishing to import EBC-46 supplements typically do so through cross-border e-commerce, which sits in a more permissive zone provided the product is for personal use.

What manufacturers should still document

Even brands that do not target the Korean market directly benefit from preparing the kind of dossier MFDS would expect. That includes a defined extraction ratio (for example, 10:1 whole-seed extract), independent third-party batch testing for heavy metals and microbiological contaminants, GMP-certified manufacturing, and clear labelling. Blushwood Health, for instance, publishes Eurofins Scientific batch reports for each production batch covering arsenic, lead, cadmium, mercury, E. coli, Salmonella, yeast and mould — a documentation level that aligns with the kind of safety data MFDS evaluators expect to see in Individually Recognised submissions.

How Korea fits into the wider picture

Korea's Individually Recognised pathway is one of several non-US frameworks that demand more upfront safety evidence than DSHEA. Comparable systems in Japan (Foods with Function Claims) and across the EU under novel food regulations create an environment where well-documented brands can enter additional markets, while less rigorously controlled products are effectively limited to jurisdictions with looser oversight. Buyers in either market benefit from the same indicators of quality: published lab results, declared extraction ratio, GMP manufacturing, and qualified medical review.

Practical takeaways for buyers

For consumers comparing EBC-46 supplement options, the practical question is not whether a brand has a Korean Individually Recognised registration — almost no brand does — but whether the brand operates to a documentation standard that would support such a registration if pursued. The simplest proxies are independent batch testing, transparent ingredient declarations, GMP manufacturing certification, and clear, accurate labelling that complies with the dietary supplement frameworks in the brand's home market.

Related articles

Swiss Swissmedic complementary medicines pathwayJapan's PMDA approach to tigilanol tiglate

Citations

1. Ministry of Food and Drug Safety (MFDS), South Korea.

2. US FDA — Dietary Supplements.

3. Blushwood Health — Eurofins Lab Test Results.

Statements about dietary supplements have not been evaluated by the Food and Drug Administration. Any blushwood-berry supplement is not intended to diagnose, treat, cure, or prevent any disease.